Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia - PubMed (original) (raw)

Review

Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia

H Bart van der Worp et al. J Neurol. 2005 Sep.

Abstract

Background: The recurrent failure of apparently promising neuroprotective drugs to improve outcome in trials of patients with acute ischaemic stroke may partially be explained by over-optimistic conclusions about efficacy as a result of methodological shortcomings in preclinical studies. We assessed the methodological quality of animal studies of five different neuroprotective agents that have been tested in 21 clinical trials including a total of more than 12,000 patients with acute ischaemic stroke.

Methods: We performed a literature search restricted to full publications on the effects of clomethiazole, gavestinel, lubeluzole, selfotel, or tirilazad mesylate on infarct volume or functional outcome in animal models of acute focal cerebral ischaemia. We used a rating scale to assess the methodological quality of the included studies. One point was attributed to each of 10 items. A score of 4 to 6 points was considered "medium" and a score above 7 "high."

Results: A total of 45 articles were included. The median score on the methodological quality index was 3; 18 studies had a medium score and one a high score. Randomised treatment allocation was mentioned in 19 studies (42 %), blinded administration of study medication in 10 (22 %), and blinded outcome assessment in 18 (40 %). The study drug was administered at a median of 10 min (range, -60 to 360 min) after the onset of ischaemia.

Conclusion: The evidence for neuroprotective efficacy that formed the basis for initiating the 21 trials was obtained in animal studies with a methodological quality that would, in retrospect, not justify such a decision. More rigorous preclinical study methodology may lead to more reliable and reproducible results.

PubMed Disclaimer

Similar articles

• Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.
  Philip M, Benatar M, Fisher M, Savitz SI. Philip M, et al. Stroke. 2009 Feb;40(2):577-81. doi: 10.1161/STROKEAHA.108.524330. Epub 2008 Dec 12. Stroke. 2009. PMID: 19074479
• [In vivo exploration of cerebral ischemia: use of neuroprotective agents in animal studies].
  Lestage P, Lockhart B, Roger A. Lestage P, et al. Therapie. 2002 Nov-Dec;57(6):554-63. Therapie. 2002. PMID: 12666263 Review. French.
• Neuroprotection in cerebral ischaemia: facts and fancies--the need for new approaches.
  Wahlgren NG, Ahmed N. Wahlgren NG, et al. Cerebrovasc Dis. 2004;17 Suppl 1:153-66. doi: 10.1159/000074808. Cerebrovasc Dis. 2004. PMID: 14694293 Review.
• To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents?
  Hunter AJ, Mackay KB, Rogers DC. Hunter AJ, et al. Trends Pharmacol Sci. 1998 Feb;19(2):59-66. doi: 10.1016/s0165-6147(97)01157-7. Trends Pharmacol Sci. 1998. PMID: 9550943 Review.
• Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies.
  Meloni BP, Zhu H, Knuckey NW. Meloni BP, et al. Magnes Res. 2006 Jun;19(2):123-37. Magnes Res. 2006. PMID: 16955724 Review.

Cited by

• A program for solving the brain ischemia problem.
  DeGracia DJ. DeGracia DJ. Brain Sci. 2013 Apr 8;3(2):460-503. doi: 10.3390/brainsci3020460. Brain Sci. 2013. PMID: 24961411 Free PMC article.
• Effect of uric acid in animal models of ischemic stroke: A systematic review and meta-analysis.
  Aliena-Valero A, Baixauli-Martín J, Castelló-Ruiz M, Torregrosa G, Hervás D, Salom JB. Aliena-Valero A, et al. J Cereb Blood Flow Metab. 2021 Apr;41(4):707-722. doi: 10.1177/0271678X20967459. Epub 2020 Nov 19. J Cereb Blood Flow Metab. 2021. PMID: 33210575 Free PMC article.
• Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations.
  Kimmelman J, London AJ, Ravina B, Ramsay T, Bernstein M, Fine A, Stahnisch FW, Emborg ME. Kimmelman J, et al. Mov Disord. 2009 Oct 15;24(13):1893-901. doi: 10.1002/mds.22712. Mov Disord. 2009. PMID: 19672990 Free PMC article.
• Can animal models of disease reliably inform human studies?
  van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR. van der Worp HB, et al. PLoS Med. 2010 Mar 30;7(3):e1000245. doi: 10.1371/journal.pmed.1000245. PLoS Med. 2010. PMID: 20361020 Free PMC article.
• Age and Sex Are Critical Factors in Ischemic Stroke Pathology.
  Roy-O'Reilly M, McCullough LD. Roy-O'Reilly M, et al. Endocrinology. 2018 Aug 1;159(8):3120-3131. doi: 10.1210/en.2018-00465. Endocrinology. 2018. PMID: 30010821 Free PMC article. Review.

References

1. 1. Stroke. 2002 Jan;33(1):308-9 - PubMed
2. 1. Stroke. 2000 Dec;31(12 ):2912-9 - PubMed
3. 1. Lancet. 2002 Feb 23;359(9307):696-700 - PubMed
4. 1. Stroke. 2002 Aug;33(8):2123-36 - PubMed
5. 1. Stroke. 2001 Jul;32(7):1598-606 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer